User login
Supplement Editor:
Marc C. Hochberg, MD, MPH
Contents
Preface and Foreword
Marc C. Hochberg, MD, MPH
Development and clinical application of COX-2–selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
Clifton G. Bingham III, MD
Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility
Bruce N. Cronstein, MD
COX-2–selective inhibitors in the treatment of arthritis
Thomas J. Schnitzer, MD, PhD, and Marc C. Hochberg, MD, MPH
Gastrointestinal safety and tolerability of non-selective nonsteroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors
David A. Peura, MD
Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors
James M. Scheiman, MD
Current perspective on the cardiovascular effects of coxibs
Marvin A. Konstam, MD, and Matthew R. Weir, MD
Renal effects of nonselective NSAIDs and coxibs
Matthew R. Weir, MD
Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy
A. Mark Fendrick, MD
Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain
Warren A. Katz, MD
Emerging options with coxib therapy
Mark J. Lema, MD, PhD
Supplement Editor:
Marc C. Hochberg, MD, MPH
Contents
Preface and Foreword
Marc C. Hochberg, MD, MPH
Development and clinical application of COX-2–selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
Clifton G. Bingham III, MD
Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility
Bruce N. Cronstein, MD
COX-2–selective inhibitors in the treatment of arthritis
Thomas J. Schnitzer, MD, PhD, and Marc C. Hochberg, MD, MPH
Gastrointestinal safety and tolerability of non-selective nonsteroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors
David A. Peura, MD
Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors
James M. Scheiman, MD
Current perspective on the cardiovascular effects of coxibs
Marvin A. Konstam, MD, and Matthew R. Weir, MD
Renal effects of nonselective NSAIDs and coxibs
Matthew R. Weir, MD
Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy
A. Mark Fendrick, MD
Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain
Warren A. Katz, MD
Emerging options with coxib therapy
Mark J. Lema, MD, PhD
Supplement Editor:
Marc C. Hochberg, MD, MPH
Contents
Preface and Foreword
Marc C. Hochberg, MD, MPH
Development and clinical application of COX-2–selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
Clifton G. Bingham III, MD
Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility
Bruce N. Cronstein, MD
COX-2–selective inhibitors in the treatment of arthritis
Thomas J. Schnitzer, MD, PhD, and Marc C. Hochberg, MD, MPH
Gastrointestinal safety and tolerability of non-selective nonsteroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors
David A. Peura, MD
Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors
James M. Scheiman, MD
Current perspective on the cardiovascular effects of coxibs
Marvin A. Konstam, MD, and Matthew R. Weir, MD
Renal effects of nonselective NSAIDs and coxibs
Matthew R. Weir, MD
Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy
A. Mark Fendrick, MD
Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain
Warren A. Katz, MD
Emerging options with coxib therapy
Mark J. Lema, MD, PhD
